Key statistics
On Friday, 89Bio Inc (ETNB:NMQ) closed at 7.19, 9.35% above its 52-week low of 6.58, set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.27 |
---|---|
High | 7.37 |
Low | 7.12 |
Bid | 7.10 |
Offer | 8.00 |
Previous close | 7.16 |
Average volume | 721.94k |
---|---|
Shares outstanding | 105.91m |
Free float | 105.20m |
P/E (TTM) | -- |
Market cap | 761.49m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 21:00 BST.
More ▼
Announcements
- 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
- 89bio to Participate in Upcoming Investor Conferences
- 89bio Appoints Francis Sarena as Chief Operating Officer
- 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
- 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
- 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
- 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
More ▼